Headquartered in Boseman, MT, but having research faciliites in San Francisco, SiteOne is is developing novel therapeutics and diagnostics safely, effectively and efficiently to treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Built around proprietary technology in the area of sodium channels exclusively licensed from Stanford University, the firm's leading therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Na?1.7, which plays a critical role in the generation and conduction of pain signals. SiteOne has developed long-duration local anesthetic molecules, PET ligands designed to identify pain generating sites, wrinkle ameliorating cosmetics, and means of producing sodium channel subtype specific blockers that could be used as orally-active analgesics.
